Premium
EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH
Author(s) -
Lee Dean A.,
Tatevian Nina,
Herring Ruth A.,
McClain Kenneth L.
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21121
Subject(s) - medicine , lymphoproliferative disease , context (archaeology) , chemotherapy , blood cancer , immunology , virus , disease , langerhans cell histiocytosis , epstein–barr virus , refractory (planetary science) , lymphoproliferative disorders , lymphoma , cancer , pathology , paleontology , physics , astrobiology , biology
Abstract Epstein–Barr virus (EBV) is a herpesvirus for which latent infection in B lymphocytes occurs in most individuals by middle childhood. Clinically significant reactivation of this virus occurs in the context of suppressed cell‐mediated immunity, occasionally developing into lymphoproliferative disease (EBV‐LPD). EBV reactivation is rarely associated with intensive chemotherapy alone. Here we present the case of a 4‐year‐old female who developed EBV‐LPD as a complication of prolonged immunosuppressive chemotherapy for her multiply‐recurrent Langerhans cell histiocytosis (LCH). Pediatr Blood Cancer 2008;50:728–730. © 2007 Wiley‐Liss, Inc.